Please login to the form below

Not currently logged in
Email:
Password:

Synthetic Biologics hires Michael Kaleko as scientific director

Co-founder of Advanced Vision Therapies joins US biotech developing synthetic DNA-based treatments

Synthetic Biologics, a US biotech specialised in developing synthetic DNA-based treatments, has appointed Dr Michael Kaleko as its new scientific director.

Kaleko, who has been a biotech consultant since 2010, has worked in gene therapy for over 20 years and previously co-founded eyecare specialist Advanced Vision Therapies in 2002, before serving as the company's president and chief scientific officer.

Prior to this he co-directed research at Genetic Therapy, a subsidiary of Novartis, where he developed multiple gene transfer and gene expression platform technologies for haemophilia, cancer, diabetes and ocular diseases.

"We are pleased to welcome Mike to the Synthetic Biologics' team,” said Jeffrey Riley, CEO and chair at Synthetic Biologics.

“We expect that Mike's significant accomplishments in the field of gene therapy will be valuable assets as we continue the work to build our portfolio of synthetic biologics and DNA-based human therapeutics."

20th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics